Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.

Publikation

Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study.

Wissenschaftlicher Artikel/Review - 01.12.2023

Neubauer Moritz C, Nicolas Guillaume, Bauman Andreas, Fani Melpomeni, Nitzsche Egbert U, Afshar-Oromieh Ali, Forrer Flavio, Rentsch Cyrill A, Stenner-Liewen Frank, Templeton Arnoud J, Schäfer Niklaus G, Wild Damian, Chirindel Alin, all investigators on behalf of the SSNM Therapy Working Group

Zitation

Neubauer M, Nicolas G, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, Forrer F, Rentsch C, Stenner-Liewen F, Templeton A, Schäfer N, Wild D, Chirindel A, all investigators on behalf of the SSNM Therapy Working Group. Early response monitoring during [Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. Eur J Nucl Med Mol Imaging 2023

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Eur J Nucl Med Mol Imaging 2023

Veröffentlichungsdatum

01.12.2023

eISSN (Online)

1619-7089

Kurzbeschreibung/Zielsetzung

To assess early tumor response with quantitated SPECT/CT and to correlate it with clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with Lutetium-PSMA I&T therapy.